

on or before July 6, 2026. Such persons may also file a written request for a hearing on the application on or before July 6, 2026.

ADDRESSES: The Drug Enforcement Administration requires that all comments be submitted electronically through the Federal eRulemaking Portal, which provides the ability to type short comments directly into the comment field on the web page or attach a file for lengthier comments. Please go to <https://www.regulations.gov> and follow the online instructions at that site for submitting comments. Upon submission of your comment, you will receive a Comment Tracking Number. Please be aware that submitted comments are not instantaneously available for public view on <https://www.regulations.gov>. If you have received a Comment Tracking Number, your comment has been successfully submitted and there is no need to resubmit the same comment.

SUPPLEMENTARY INFORMATION: In accordance with 21 CFR 1301.33(a), this is notice that on April 15, 2026, ANI Pharmaceuticals Inc., 70 Lake Drive, East Windsor, New Jersey 08520, applied to be registered as a bulk manufacturer of the following basic class(es) of controlled substance(s):

Controlled substance	Drug code	Schedule
Levorphanol	9220	II

The company plans to bulk manufacture the listed controlled substance for development and eventual use in a commercial drug product. No other activity for this drug code is authorized for this registration.

Thomas Prevoznik,
Deputy Assistant Administrator.
[FR Doc. 2026-08586 Filed 5-1-26; 8:45 am]
BILLING CODE 4410-09-P

DEPARTMENT OF JUSTICE

Drug Enforcement Administration
[Docket No. DEA-1709]

Bulk Manufacturer of Controlled Substances Application: Patheon Pharmaceuticals Inc.

AGENCY: Drug Enforcement Administration, Justice.
ACTION: Notice of application.

SUMMARY: Patheon Pharmaceuticals Inc. has applied to be registered as a bulk manufacturer of basic class(es) of controlled substance(s). Refer to Supplementary Information listed below for further drug information.

DATES: Registered bulk manufacturers of the affected basic class(es), and applicants, therefore, may submit electronic comments on or objections to the issuance of the proposed registration on or before July 6, 2026. Such persons may also file a written request for a hearing on the application on or before July 6, 2026.

ADDRESSES: The Drug Enforcement Administration requires that all comments be submitted electronically through the Federal eRulemaking Portal, which provides the ability to type short comments directly into the comment field on the web page or attach a file for lengthier comments. Please go to <https://www.regulations.gov> and follow the online instructions at that site for submitting comments. Upon submission of your comment, you will receive a Comment Tracking Number. Please be aware that submitted comments are not instantaneously available for public view on <https://www.regulations.gov>. If you have received a Comment Tracking Number, your comment has been successfully submitted and there is no need to resubmit the same comment.

SUPPLEMENTARY INFORMATION: In accordance with 21 CFR 1301.33(a), this is notice that on March 18, 2026, Patheon Pharmaceuticals Inc., 2110 East Galbraith Road, Cincinnati, Ohio 45237-1625, applied to be registered as a bulk manufacturer of the following basic class(es) of controlled substance(s):

Controlled substance	Drug code	Schedule
Gamma Hydroxybutyric Acid.	2010	I

The company plans to bulk manufacture the listed controlled substance as an Active Pharmaceutical Ingredient that will be further synthesized into Food and Drug Administration approved dosage forms. No other activity for this drug code authorized for this registration.

Thomas Prevoznik,
Deputy Assistant Administrator.
[FR Doc. 2026-08585 Filed 5-1-26; 8:45 am]
BILLING CODE P

DEPARTMENT OF JUSTICE

Notice of Lodging of Proposed Consent Decree Under the Resource Conservation and Recovery Act

On April 28, 2026, the Department of Justice lodged a proposed Consent Decree with the United States District Court for the Southern District of Ohio

in the lawsuit entitled *United States et al. v. AK Steel Corp.*, Civil Action No. 1:00-cv-00530-JPH.

In 2001, the United States brought an action against Defendant AK Steel Corporation, now named Cleveland-Cliffs Steel Corporation, seeking among other things Defendant's performance of corrective actions under Section 3008(h) of the Resource Conservation Recovery Act ("RCRA"), 42 U.S.C. 6928(h), to address releases of hazardous waste at Defendant's Middletown Works steel production facility in Middletown, Ohio. On May 15, 2006, the Court entered a Consent Decree in Partial Resolution of Pending Claims (the "2006 Consent Decree") which resolved all claims brought by plaintiffs except for the United States' (and intervening plaintiffs') claims for corrective action under RCRA Section 3008(h). The 2006 Consent Decree required Defendant to perform various corrective action investigations under Section 3008(h) of RCRA, but the Parties agreed to defer resolution of the alleged liability of Defendant under Section 3008(h) of RCRA and to defer entering into an agreement governing implementation of such corrective measures until completion of the investigations. The Consent Decree lodged today establishes requirements for Defendant to complete corrective actions at seven areas in and around the Facility, which Defendant has been developing with EPA oversight pursuant to the 2006 CD. The Consent Decree thus resolves the last pending claim in this case.

The publication of this notice opens a period for public comment on the Consent Decree. Comments should be addressed to the Principal Deputy Assistant Attorney General, Environment and Natural Resources Division, and should refer to *United States et al. v. AK Steel Corp.*, D.J. Ref. No. 90-5-2-1-2189/4. All comments must be submitted no later than thirty (30) days after the publication date of this notice. Comments may be submitted either by email or by mail:

To submit comments:	Send them to:
By email	pubcomment-ees.enrd@usdoj.gov
By mail	Principal Deputy Assistant Attorney General, U.S. DOJ—ENRD, P.O. Box 7611, Washington, DC 20044-7611.

Any comments submitted in writing may be filed by the United States in whole or in part on the public court docket without notice to the commenter.

During the public comment period, the Consent Decree may be examined and downloaded at this Justice Department website: <https://www.justice.gov/enrd/consent-decrees>. If you require assistance accessing the Consent Decree, you may request assistance by email or by mail to the addresses provided above for submitting comments.

Thomas Carroll,

Assistant Section Chief, Environmental Enforcement Section, Environment and Natural Resources Division.

[FR Doc. 2026-08581 Filed 5-1-26; 8:45 am]

BILLING CODE 4410-CW-P

DEPARTMENT OF LABOR

Employee Benefits Security Administration

[Prohibited Transaction Exemption 2026-03; Application Number D-12118]

Exemption for Certain UBS AG (UBS) Asset Managers Located in Zurich, Switzerland

AGENCY: Employee Benefits Security Administration, Labor.

ACTION: Notice of exemption.

SUMMARY: This exemption allows current and future UBS-related asset managers to continue to rely on Prohibited Transaction Exemption (PTE) 84-14, from May 5, 2026, to May 5, 2035, if certain conditions are met, notwithstanding four convictions and one non-prosecution agreement involving affiliated entities of UBS.

DATES: *Exemption date:* This exemption will be in effect for the period beginning on May 5, 2026, and ending on May 5, 2035.

FOR FURTHER INFORMATION CONTACT: Nicholas Schroth, Office of Exemption Determinations, Employee Benefits Security Administration, U.S. Department of Labor, (202) 693-8540 (this is not a toll-free number).

SUPPLEMENTARY INFORMATION:

Benefits of the Exemption

This exemption is intended to protect Covered Plans¹ from incurring the

¹ “Covered Plan” is defined in Section I(e) to mean a plan subject to Part IV of Title I of ERISA (an “ERISA-covered plan”) or a plan subject to Code section 4975 (an “IRA”), in each case, with respect to which an Affiliated QPAM, as defined in Section I(b), relies on PTE 84-14, or with respect to which an Affiliated QPAM (or any UBS affiliate) has expressly represented that the manager qualifies as a QPAM or relies on PTE 84-14. A Covered Plan does not include an ERISA-covered plan or IRA to the extent the Affiliated QPAM has expressly disclaimed reliance on QPAM status or PTE 84-14

harms and costs that UBS represents would arise if UBS Qualified Professional Asset Managers (QPAMs) are no longer able to rely on the relief described in PTE 84-14, due to UBS QPAMs’ noncompliance with that class exemption. Among other things, this exemption ensures that a Covered Plan can terminate its relationship with a UBS QPAM in an orderly and cost-effective fashion if the Covered Plan fiduciary determines that it is prudent to do so. This exemption requires UBS QPAMs to adhere to basic fiduciary standards and responsibilities mandated by Title I of ERISA and the Code and reinforces the obligation of UBS QPAMs to act with integrity on behalf of Covered Plans, as required by PTE 84-14.

Background

UBS requested an exemption in accordance with the Department’s exemption procedures.² On February 26, 2026, the Department published a notice of proposed exemption in the **Federal Register** (the Proposed Exemption),³ for certain current and future UBS-related asset managers to continue to rely on PTE 84-14 until May 4, 2031, if certain conditions are met, notwithstanding four judgments of conviction and one non-prosecution agreement involving entities within UBS’s corporate umbrella. Based on the record and representations made by UBS, the Department has determined to grant the Proposed Exemption with the modifications discussed below.

This exemption provides only the relief specified herein and does not provide relief from any other law. If any material statement in the record attributable to this exemption is not, or may no longer be, completely and factually accurate, UBS must immediately alert the Department.

in entering into a contract, arrangement, or agreement with the ERISA-covered plan or IRA. Notwithstanding the above, an Affiliated QPAM may disclaim reliance on QPAM status or PTE 84-14 in a written modification of a contract, arrangement, or agreement with an ERISA-covered plan or IRA, where: the modification is made in a bilateral document signed by the client; the client’s attention is specifically directed toward the disclaimer; and the client is advised in writing that, with respect to any transaction involving the client’s assets, the Affiliated QPAM will not represent that it is a QPAM, and will not rely on the relief described in PTE 84-14.

² 29 CFR part 2570, subpart B at 89 FR 4662, January 24, 2024. Effective December 31, 1978, section 102 of Reorganization Plan No. 4 of 1978, 5 U.S.C. App. 1 (1996), transferred the authority of the Secretary of the Treasury to issue exemptions of the type requested by the Applicant to the Secretary of Labor. Therefore, this notice of exemption is issued solely by the Department.

³ See 91 FR 9645.

Written Comments

In the Proposed Exemption, the Department invited all interested persons to submit written comments and request a public hearing. All comments and requests for a hearing were due to the Department by April 6, 2026. The Department received written comments from Mr. Larry Dembrun, SIFMA, and UBS, and no requests for a public hearing.⁴

Comment From Mr. Larry Dembrun

Mr. Dembrun stated that he “understood the intent behind the [regulation]” and “encourage[d] decision-makers to carefully consider how its implementation may affect communities that are already facing financial and operational challenges.” He also asked the Department to engage a broad range of stakeholders and to incorporate their feedback before finalizing the exemption.

Department Response: The implementation of this exemption allows UBS QPAMs to continue to rely on PTE 84-14 to engage in a wide range of transactions that are beneficial to Covered Plans, notwithstanding that the UBS QPAMs fail to comply with Section I(g) of that class exemption. This exemption, therefore, preserves the ability of Covered Plans to retain their asset manager of choice and potentially avoid the financial and operational challenges associated with transitioning their assets to a new asset manager. These costs are described in the Proposed Exemption. Further, by permitting UBS QPAMs to continue to rely on PTE 84-14, this exemption allows UBS QPAMs to manage Covered Plan assets more efficiently.

With respect to Mr. Dembrun’s request that the Department engage a broad range of stakeholders, the Department notes that UBS provided a notice of the Proposed Exemption to all UBS Covered Plan clients and notice of the Proposed Exemption was published in the **Federal Register**. In developing administrative exemptions, the Department welcomes and considers carefully comments from stakeholders, which become part of the public record.

Comment From SIFMA

SIFMA raised general concerns regarding the impact of PTE 84-14’s disqualification provisions. SIFMA also broadly stated that the individual exemptions issued as a result of UBS QPAM disqualification contain punitive

⁴ All information submitted by the Applicant to the Department in connection with this exemption is available through the Department’s Public Disclosure Room, by referencing D-12118.